American Oriental Bioengineering Inc (AOB) Financial Statements (2024 and earlier)
Company Profile
Business Address |
NO, 4018 JINTIAN ROAD, ANLIAN PLAZA FUTIAN, DISTRICT SHENZHEN, 518026 |
State of Incorp. | CO |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
9/30/2013 MRQ | 12/31/2012 | 12/31/2011 | |||
---|---|---|---|---|---|
ASSETS | |||||
Current Assets | |||||
Cash, cash equivalents, and short-term investments | 7,097 | ✕ | |||
Cash and cash equivalents | 7,097 | ✕ | |||
Receivables | 45,544 | ✕ | |||
Inventory, net of allowances, customer advances and progress billings | ✕ | 20,571 | ✕ | ||
Inventory | 20,571 | ✕ | |||
Prepaid expense | 227 | ✕ | |||
Advances on inventory purchases | 10,065 | ✕ | |||
Other current assets | 719 | ✕ | |||
Other undisclosed current assets | 11,225 | ✕ | |||
Total current assets: | 95,448 | ✕ | |||
Noncurrent Assets | |||||
Property, plant and equipment | 171,381 | ✕ | |||
Long-term investments and receivables | 3,337 | ✕ | |||
Long-term investments | 3,337 | ✕ | |||
Intangible assets, net (including goodwill) | ✕ | 145,315 | ✕ | ||
Intangible assets, net (excluding goodwill) | 145,315 | ✕ | |||
Deferred costs | 267 | ✕ | |||
Other undisclosed noncurrent assets | 30,560 | ✕ | |||
Total noncurrent assets: | 350,860 | ✕ | |||
TOTAL ASSETS: | 446,309 | ✕ | |||
LIABILITIES AND EQUITY | |||||
Liabilities | |||||
Current Liabilities | |||||
Accounts payable and accrued liabilities | 28,107 | ✕ | |||
Taxes payable | 763 | ✕ | |||
Accounts payable | 11,005 | ✕ | |||
Accrued liabilities | 16,339 | ✕ | |||
Debt | 6,873 | ✕ | |||
Other undisclosed current liabilities | 71,231 | ✕ | |||
Total current liabilities: | 106,212 | ✕ | |||
Noncurrent Liabilities | |||||
Long-term debt and lease obligation | 555 | ✕ | |||
Long-term debt, excluding current maturities | 555 | ✕ | |||
Liabilities, other than long-term debt | 11,956 | ✕ | |||
Deferred tax liabilities, net | 11,956 | ✕ | |||
Total noncurrent liabilities: | 12,511 | ✕ | |||
Total liabilities: | 118,722 | ✕ | |||
Equity | |||||
Equity, attributable to parent, including: | 327,587 | ✕ | |||
Preferred stock | 1 | ✕ | |||
Common stock | 73 | ✕ | |||
Treasury stock, value | (800) | ✕ | |||
Additional paid in capital | 177,974 | ✕ | |||
Accumulated other comprehensive income | 71,790 | ✕ | |||
Retained earnings | 78,098 | ✕ | |||
Other undisclosed equity, attributable to parent | 451 | ✕ | |||
Total equity: | 327,587 | ✕ | |||
TOTAL LIABILITIES AND EQUITY: | 446,309 | ✕ |
Income Statement (P&L) ($ in thousands)
9/30/2013 TTM | 12/31/2012 | 12/31/2011 | ||
---|---|---|---|---|
Revenues | 145,100 | ✕ | ||
Cost of revenue | (100,742) | ✕ | ||
Gross profit: | 44,358 | ✕ | ||
Operating expenses | (130,689) | ✕ | ||
Operating loss: | (86,331) | ✕ | ||
Nonoperating income (Other Nonoperating income) | 379 | ✕ | ||
Interest and debt expense | 36,138 | ✕ | ||
Loss from continuing operations before equity method investments, income taxes: | (49,814) | ✕ | ||
Loss from equity method investments | (2,813) | ✕ | ||
Other undisclosed loss from continuing operations before income taxes | (4,874) | ✕ | ||
Loss from continuing operations before income taxes: | (57,501) | ✕ | ||
Income tax expense | (2,224) | ✕ | ||
Loss from continuing operations: | (59,725) | ✕ | ||
Loss before gain (loss) on sale of properties: | (59,725) | ✕ | ||
Net loss: | (59,725) | ✕ | ||
Net income attributable to noncontrolling interest | 12 | ✕ | ||
Net loss available to common stockholders, diluted: | (59,713) | ✕ |
Comprehensive Income ($ in thousands)
9/30/2013 TTM | 12/31/2012 | 12/31/2011 | ||
---|---|---|---|---|
Net loss: | (59,725) | ✕ | ||
Comprehensive loss: | (59,725) | ✕ | ||
Comprehensive loss, net of tax, attributable to noncontrolling interest | (12) | ✕ | ||
Other undisclosed comprehensive income, net of tax, attributable to parent | 4,092 | ✕ | ||
Comprehensive loss, net of tax, attributable to parent: | (55,646) | ✕ |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.